Related Experiment Video
Updated: Sep 23, 2025

The Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy rNAION
Published on: November 20, 2016
Non-arteritic anterior ischaemic optic neuropathy (NA-AION) and COVID-19 vaccination
Srinivasan Sanjay1, Isha Acharya2, Abdul Rawoof3
1Uveitis and Ocular Immunology, Narayana Nethralaya, Bangalore, Karnataka, India sanjaygroup24@gmail.com.
Abstract:
A woman in her 50s presented with diminution of vision in her left eye (OS) 4 days after COVISHIELDTM vaccination. She had been diagnosed with non-arteritic anterior ischaemic optic neuropathy (NA-AION) of right eye (OD) 8 months earlier. The present episode revealed a best-corrected visual acuity (BCVA) of 20/50 in OD and 20/20 in OS with grade 1 relative afferent pupillary defect. Fundus evaluation showed pale disc in OD and temporal disc oedema in OS. Humphrey's visual field analysis showed incomplete inferior altitudinal defect in OD and a centro-caecal scotoma in OS. Systemic investigations were normal. OS was diagnosed with NA-AION. She was started on oral aspirin 75 mg. At 1-month follow-up, disc oedema of OS had resolved with BCVA maintaining at 20/20. The patient was lost to follow-up later. The relationship between the vaccine and the ocular event is temporal with no causal association.
Related Concept Videos
Angle Closure Glaucoma: Treatment
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview
Photoreceptors and Visual Pathways

